SCHEMBL3694041

SCHEMBL3694041

CC(NC(=O)c1nc2c(C(F)(F)F)cc(-c3ccoc3)cn2c1Cl)c1cccs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
PKM P14618 2/20 0.37
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
PTGER4 P35408 1/20 0.34
KDM4E B2RXH2 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
ERN1 O75460 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
PDE2A O00408 1/20 0.31
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
KCNT1 Q5JUK3 2/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TRPV1 Q8NER1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7498501 0.89 PKM (0.36) ALDH1A1PKMPTGER4RXFP1ERN1
SCHEMBL7495089 0.87 KDM4E (0.42) ALDH1A1POLBMAPTHPGDPKM
SCHEMBL7494518 0.87 PTGER4 (0.40) ALDH1A1PTGER4PDE2A
SCHEMBL7494962 0.87 PTGER4 (0.40) ALDH1A1PTGER4PDE2A
SCHEMBL7494833 0.83 PKM (0.44) ALDH1A1POLBMAPTHPGDPKM
SCHEMBL7494058 0.78 PKM (0.44) ALDH1A1MAPTHPGDPKMKDM4E
SCHEMBL7494524 0.78 HCRTR1 (0.41) MAPTPKMRXFP1
SCHEMBL3694043 0.78 AR (0.36) ALDH1A1PKMERN1MEN1KMT2A
SCHEMBL7500383 0.78 HCRTR1 (0.41) MAPTPKMRXFP1
SCHEMBL3793277 0.78 NOTUM (0.41) ALDH1A1MAPTPKMKDM4ERXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 ALDH1A1 1337/4885POLB 1134/4885MAPT 1692/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 ALDH1A1 1337/4885POLB 1134/4885MAPT 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.